CCA
REGN icon

Cora Capital Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Cora Capital Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$222K Sell
356
-3
-0.8% -$2.04K 0.06% 128
2026
Q1 		$277K Buy
359
+95
+36% +$72.7K 0.09% 100
2025
Q4 		$204K Buy
+264
New +$179K 0.08% 128

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Cora Capital Advisors's REGN Position: Q2 2026 in Review

Cora Capital Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 0.84% in Q2 2026, selling an estimated $2.04K and leaving 356 shares worth $222K. The position accounts for 0.06% of the portfolio, ranked #128.

Cora Capital Advisors first reported a position in REGN in Q4 2025 and has held it in 3 quarters since. The position peaked at $277K in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Cora Capital Advisors held 356 shares of Regeneron Pharmaceuticals worth $222K as of Q2 2026.
  • Cora Capital Advisors sold 3 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $2.04K.
  • Regeneron Pharmaceuticals made up 0.06% of Cora Capital Advisors's portfolio in Q2 2026, its #128 holding.
  • Cora Capital Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Cora Capital Advisors's Regeneron Pharmaceuticals position peaked at $277K in Q1 2026.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Cora Capital Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.